keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy of lung cancer

keyword
https://www.readbyqxmd.com/read/29454534/sarcomatoid-carcinoma-of-the-lung-the-mayo-clinic-experience-in-127-patients
#1
Kunlatida Maneenil, Zhiqiang Xue, Ming Liu, Jennifer Boland, Fengying Wu, Shawn M Stoddard, Julian Molina, Ping Yang
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is an unusual form of non-small-cell lung cancer (NSCLC). Because of its rarity and heterogeneity, the treatment and prognosis of PSC have not been clearly described. METHODS AND MATERIALS: We retrospectively evaluated all patients with a diagnosis of PSC from 1997 to 2015 at the Mayo Clinic (Rochester, MN). The clinical characteristics, treatment details, and outcomes were collected. The survival rates of the PSC patients were compared with those for other subtypes of NSCLC...
December 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29453000/neoadjuvant-chemoradiation-shows-no-survival-advantage-to-chemotherapy-alone-in-stage-iiia-patients
#2
Seth B Krantz, Brian Mitzman, Waseem Lutfi, Kristine Kuchta, Chi-Hsiung Wang, John A Howington, Ki Wan Kim
BACKGROUND: For operable patients with clinical stage IIIA non-small cell lung cancer, the optimum neoadjuvant treatment strategy remains unclear. Our aim was to compare perioperative and long-term outcomes for patients receiving neoadjuvant chemoradiotherapy (NCRT) versus neoadjuvant chemotherapy (NCT) alone. METHODS: We queried the National Cancer Database to identify all patients with N2 and either T1-T2 non-small cell lung cancer who received either NCRT or NCT followed by lobectomy between 2006 and 2012...
February 13, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29425685/out-of-the-darkness-and-into-the-light-new-strategies-for-improving-treatments-for-locally-advanced-non-small-cell-lung-cancer
#3
Yun Zhang, Qin Lin, Ting Xu, Weiye Deng, Jinming Yu, Zhongxing Liao, Jinbo Yue
The standard treatment for locally advanced non-small cell lung cancer (LA NSCLC) includes surgery, radiotherapy, chemotherapy, or some combination of these modalities. Many clinical trials have been conducted in attempts to intensify treatment for LA NSCLC, but with little improvement. A therapeutic plateau had been reached, with no major progress in extending survival for patients with this disease. However, several recent trials of newer targeted therapies and immunotherapies may shed new light on potential therapeutic breakthroughs...
February 6, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29410947/before-or-after-evolving-neoadjuvant-approaches-to-locally-advanced-non-small-cell-lung-cancer
#4
REVIEW
Jennifer Lewis, Erin A Gillaspie, Evan C Osmundson, Leora Horn
The treatment of patients with stage IIIA ( N 2) non-small cell lung cancer (NSCLC) is one of the most challenging and controversial areas of thoracic oncology. This heterogeneous group is characterized by varying tumor size and location, the potential for involvement of surrounding structures, and ipsilateral mediastinal lymph node spread. Neoadjuvant chemotherapy, administered prior to definitive local therapy, has been found to improve survival in patients with stage IIIA ( N 2) NSCLC. Concurrent chemoradiation has also been evaluated in phase III studies in efforts to improve control of locoregional disease...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29394804/-a-case-of-synchronous-quadruple-cancers-treated-with-neoadjuvant-chemotherapy-followed-by-surgery
#5
Keiji Muramoto, Toru Miyake, Tomoharu Shimizu, Hiromichi Sonoda, Tomoyuki Ueki, Yoshitaka Terada, Haruki Mori, Hiromitsu Maehira, Katsushi Takebayashi, Sachiko Kaida, Hiroya Iida, Tsuyoshi Yamaguchi, Masaji Tani
The patient is male in his 60's. He underwent endoscopic examination for anemia, which was found during screening of high PSA value. Endoscopic examination revealed a gastric cancer and 3 colorectal cancers. Histological results from biopsy was HER2 positive poorly differentiated adenocarcinoma in gastric tumor and moderately differentiated adenocarcinoma in colorectal tumor. Chest CT showed a pulmonary nodule in the middle right lung. Histological diagnosis was TTF-1 positive adenocarcinoma, meaning primary lung cancer...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29362322/-a-case-of-resected-superior-sulcus-tumor-with-pathological-complete-response-after-trimodality-therapy
#6
Masaya Nishino, Kenji Tomizawa, Syuta Ohara, Toshio Fujino, Yuichi Sesumi, Takamasa Koga, Katsuaki Sato, Yoshihisa Kobayashi, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Tetsuya Mitsudomi
The current case was 73-year-oldwoman. She was referredto our hospital for an abnormal shadow of chest X-ray in the upper right lung field. Chest CT showed 3.5 cm of tumor located at the apex of right lobe with invasion of the chest wall. The tumor was diagnosed as squamous cell carcinoma using CT guided needle biopsy(superior sulcus tumor, clinical T3N0M0, Stage II B). The neoadjuvant therapy, 4 courses of chemotherapy(CBDCA plus PTX)andconcurrent radiotherapy(45 Gy/25 Fr)was performed. Chest CT revealed that tumor size was decreased to 2...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29357969/-surgical-procedures-and-perioperative-management-for-non-small-cell-lung-cancer-complicated-with-left-atrial-tumor-thrombus
#7
Tong Bao, Fei Xiao, Deruo Liu, Yongqing Guo, Chaoyang Liang
BACKGROUND: Non-small cell lung cancer with left atrial tumor thrombus accounts for a small proportion of local advanced lung cancer. Whether surgery could bring benefits, as well as surgical options are still controversial, and have always been hot spots in surgical research. We report a single center experience of surgical treatment to non-small cell lung cancer with left atrial tumor thrombus, aim to figure out more reasonable treatment strategy. METHODS: From August 2006 to July 2017, a total of 11 cases of non-small cell lung cancer with left atrial tumor thrombus underwent surgery in Thoracic Surgery Department of China-Japan Friendship Hospital...
January 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29338734/comparing-the-benefits-of-chemoradiotherapy-and-chemotherapy-for-resectable-stage-iii-a-n2-non-small-cell-lung-cancer-a-meta-analysis
#8
REVIEW
Yuqiao Chen, Xiong Peng, Yuan Zhou, Kun Xia, Wei Zhuang
BACKGROUND: Induction chemotherapy has been shown to improve survival of patients with stage III A/N2 (T1-3, N2, M0) non-small cell lung cancer (NSCLC), followed by resection, but the benefits of neoadjuvant radiotherapy still remain controversial. METHODS: PubMed, Embase, and Cochrane library databases were searched for relevant randomized controlled trials (RCTs) comparing the outcomes of induction chemoradiotherapy over induction chemotherapy, in patients with resectable stage IIIA/N2 NSCLC...
January 16, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29314062/postneoadjuvant-adjuvant-chemotherapy-in-resected-n1-non-small-cell-lung-cancer-with-residual-nodal-disease
#9
James W Smithy, Joshua E Rosen, Sarah J Gao, Anthony W Kim
BACKGROUND AND OBJECTIVES: Nodal positivity following neoadjuvant chemotherapy in locally advanced non-small cell lung cancer (NSCLC) is considered a poor prognostic sign, but little data are available on the efficacy of adjuvant chemotherapy in these cases. This analysis sought to determine whether adjuvant chemotherapy was associated with increased survival in NSCLC patients with residual N1 disease at resection. METHODS: Patients from the National Cancer Database (NCDB) with cN1T1-2M0 NSCLC treated with neoadjuvant chemotherapy and definitive resection between 2006 and 2012 were identified...
December 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29279354/germinal-centers-determine-the-prognostic-relevance-of-tertiary-lymphoid-structures-and-are-impaired-by-corticosteroids-in-lung-squamous-cell-carcinoma
#10
Karina Silina, Alex Soltermann, Farkhondeh Movahedian Attar, Ruben Casanova, Zina M Uckeley, Helen Thut, Muriel Wandres, Sergejs Isajevs, Phil F Cheng, Alessandra Curioni Fontecedro, Periklis Foukas, Mitchell P Levesque, Holger Moch, Aija Linē, Maries van den Broek
In solid tumors, the presence of lymph node-like structures called tertiary lymphoid structures (TLS) is associated with improved patient survival. However, little is known about how TLS form in cancer, how their function affects survival, and whether they are affected by cancer therapy. In this study, we used multi-spectral microscopy, quantitative pathology and gene expression profiling to analyze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental model of lung TLS induction...
December 26, 2017: Cancer Research
https://www.readbyqxmd.com/read/29258674/surgical-outcomes-after-neoadjuvant-chemotherapy-and-ipilimumab-for-non-small-cell-lung-cancer
#11
Chi-Fu Jeffrey Yang, Frances McSherry, Nicholas R Mayne, Xiaofei Wang, Mark F Berry, Betty Tong, David H Harpole, Thomas A D'Amico, Jared D Christensen, Neal E Ready, Jacob A Klapper
BACKGROUND: The objective of this study was to evaluate the safety and feasibility of using neoadjuvant chemotherapy plus ipilimumab followed by surgery as a treatment strategy for stage II-IIIA non-small-cell lung cancer. METHODS: From 2013 to 2017, postoperative data from patients who underwent surgery after neoadjuvant chemotherapy plus ipilimumab in the TOP1201 trial, an open label phase II trial (NCT01820754), were prospectively collected. The surgical outcomes from TOP1201 were compared with outcomes in a historical cohort of patients receiving standard preoperative chemotherapy followed by surgery identified from our institution's prospectively collected thoracic surgery database...
December 16, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29239731/practice-patterns-and-outcomes-for-pemetrexed-plus-platinum-doublet-as-neoadjuvant-chemotherapy-in-adenocarcinomas-of-lung-looking-beyond-the-usual-paradigm
#12
V Noronha, S Zanwar, A Joshi, V M Patil, A Mahajan, A Janu, J P Agarwal, P Bhargava, A Kapoor, K Prabhash
AIMS: Neoadjuvant chemotherapy (NACT) is the standard of care in non-small cell lung cancers (NSCLC) with locally advanced N2 disease. There is a scarcity of data for the pemetrexed-platinum regimen as NACT. Also, apart from N2 disease, the role of NACT in locally advanced NSCLCs for tumour downstaging is unclear. MATERIALS AND METHODS: Non-metastatic adenocarcinomas of lung treated with pemetrexed-platinum-based NACT were analysed. The patients with locoregionally advanced N2 disease and those who were borderline candidates for upfront definitive treatment were planned for NACT after discussion in a multidisciplinary clinic...
November 24, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29199698/role-of-pneumonectomy-for-lung-cancer-in-current-scenario-an-indian-perspective
#13
S H Shah, A Goel, Vpp Selvakumar, S Garg, K Siddiqui, K Kumar
BACKGROUND: Surgical treatment for lung cancer has evolved from pneumonectomy to lobectomy/sleeve resection around the world. Although condemned for poor outcomes, pneumonectomy may still be required in a select group of patients in developing countries. With the better patient selection, optimization of medical comorbidities, better perioperative care; pneumonectomy may show better results. Thus, there is a need to reconsider the role of pneumonectomy in patients with locally advanced lung cancer in the current scenario...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29199667/mediastinal-staging-for-non-small-cell-lung-cancer-revisited-it-is-being-done-under-aegis-of-icon-and-lung-cancer-consortium-asia
#14
REVIEW
D Pandey, P Ramanathan, R Pandey, K Prabhash
Mediastinal staging is a crucial factor in the decision making in patients with non-metastatic non-small cell lung cancer (NSCLC). Mediastinoscopy has historically been the gold standard for this purpose. With the advent of PET-CT, the role of an invasive staging modality like mediastinoscopy has been diminishing. Newer developments in endoscopic staging like EBUS and EUS-FNA have also provided means to get a cytological diagnosis of enlarged lymph nodes. With the meta-analyses showing encouraging results of neoadjuvant chemotherapy in operable lung cancers including the early stage disease, the sanctity of invasive mediastinal staging for the sole purpose for selecting patients for upfront surgery is debatable...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29177095/targeting-immune-checkpoints-in-breast-cancer-an-update-of-early-results
#15
REVIEW
Cinzia Solinas, Andrea Gombos, Sofiya Latifyan, Martine Piccart-Gebhart, Marleen Kok, Laurence Buisseret
The immune tumour microenvironment has been shown to play a crucial role in the development and progression of cancer. Expression of gene signatures, reflecting immune activation, and the presence of tumour-infiltrating lymphocytes were associated with favourable outcomes in HER2-positive and triple-negative breast cancer. Recently, immunotherapy with immune checkpoint blockade induced long-lasting responses and improved survival in hard-to-treat malignancies (ie, melanoma and non-small cell lung cancer) and are changing treatment paradigms in a variety of neoplastic diseases...
2017: ESMO Open
https://www.readbyqxmd.com/read/29168933/role-of-chemotherapy-and-targeted-therapy-in-early-stage-non-small-cell-lung-cancer
#16
Misako Nagasaka, Shirish M Gadgeel
Adjuvant platinum based chemotherapy is accepted as standard of care in stage II and III non-small cell lung cancer (NSCLC) patients and is often considered in patients with stage IB disease who have tumors ≥ 4 cm. The survival advantage is modest with approximately 5% at 5 years. Areas covered: This review article presents relevant data regarding chemotherapy use in the perioperative setting for early stage NSCLC. A literature search was performed utilizing PubMed as well as clinical trial.gov. Randomized phase III studies in this setting including adjuvant and neoadjuvant use of chemotherapy as well as ongoing trials on targeted therapy and immunotherapy are also discussed...
November 26, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29163832/neoadjuvant-chemotherapy-followed-by-surgery-versus-upfront-surgery-in-non-metastatic-non-small-cell-lung-cancer-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#17
Xiao-Nan Zhang, Lei Huang
Background: The favorable effect of postoperative chemotherapy on long-term survival has been well acknowledged in non-small cell lung cancer (NSCLC), while the role of neoadjuvant chemotherapy (NAC) remains obscure. This meta-analysis enrolling high-quality randomized controlled trials (RCTs) aimed at comparing NAC followed by surgery with upfront surgery (US) in efficacy and safety among non-metastatic NSCLC patients. Materials and Methods: Relevant literatures were searched systematically from MEDLINE, EMBASE, and the Cochrane Library...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136212/neoadjuvant-and-adjuvant-therapy-for-stage-iii-non-small-cell-lung-cancer
#18
Shun-Ichi Watanabe, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Hisashi Saji, Hiroshige Yoshioka, Yoshitaka Zenke, Tadashi Aoki, Yasuhiro Tsutani, Morihito Okada
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local and microscopic systemic disease, because the 5-year survival of patients with Stage III NSCLC who underwent surgical resection alone has been dismal. One way to improve surgical outcome is the administration of chemotherapy before or after the surgical procedure. During the last two decades, many clinical studies have focused on developing optimal adjuvant or neoadjuvant chemotherapy regimens that can be combined with surgical treatment and/or radiotherapy...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29130233/-clinical-features-and-prognosis-analysis-of-21-gastric-cancer-patients-with-pathological-complete-response-after-neoadjuvant-chemotherapy
#19
Liangqun Peng, Wei Yang, Zhandong Zhang, Hongxing Liu, Yawei Hua
OBJECTIVE: To evaluate the clinical features and prognosis of gastric cancer patients with pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). METHODS: Clinical data of 159 gastric cancer patients who received NAC followed by surgical resection between January 2012 and December 2014 at the Affiliated Tumor Hospital of Zhengzhou University were collected and clinical features of those with pCR were analyzed retrospectively. Kaplan-Meier method was used to estimate 3-year overall survival (OS) rate and recurrence-free survival (RFS) rate...
October 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29114590/oncological-outcomes-from-trimodality-therapy-receiving-definitive-doses-of-neoadjuvant-chemoradiation-%C3%A2-60%C3%A2-gy-and-factors-influencing-consideration-for-surgery-in-stage-iii-non-small-cell-lung-cancer
#20
Melissa A L Vyfhuis, Neha Bhooshan, Whitney M Burrows, Michelle Turner, Mohan Suntharalingam, James Donahue, Elizabeth M Nichols, Josephine Feliciano, Søren M Bentzen, Shahed Badiyan, Shamus R Carr, Joseph Friedberg, Charles B Simone, Martin J Edelman, Steven J Feigenberg, Pranshu Mohindra
Purpose: Guidelines for locally advanced non-small cell lung cancer (LA-NSCLC) recommend definitive chemoradiation therapy (CRT) for cN2-N3 disease, reserving surgery for patients with minimal nodal involvement at presentation. The current literature suggests that surgery after CRT for stage III NSCLC can improve freedom-from-recurrence (FFR) but has not consistently demonstrated an improvement in overall survival, perhaps partly due to the low (45-50.4 Gy) preoperative doses delivered that result in low rates of mediastinal nodal clearance...
July 2017: Advances in Radiation Oncology
keyword
keyword
52838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"